Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 11:11:667427.
doi: 10.3389/fonc.2021.667427. eCollection 2021.

Application of Mass Spectrometry in Pancreatic Cancer Translational Research

Peng Ge  1   2   3 , Yalan Luo  1   2 , Haiyang Chen  1   2   3 , Jiayue Liu  1   2   3 , Haoya Guo  1   2   3 , Caiming Xu  1 , Jialin Qu  2   3 , Guixin Zhang  1   2 , Hailong Chen  1   2
Affiliations
Review

Application of Mass Spectrometry in Pancreatic Cancer Translational Research

Peng Ge et al. Front Oncol. .

Abstract

Pancreatic cancer (PC) is one of the most common malignant tumors in the digestive tract worldwide, with increased morbidity and mortality. In recent years, with the development of surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, and the change of the medical thinking model, remarkable progress has been made in researching comprehensive diagnosis and treatment of PC. However, the present situation of diagnostic and treatment of PC is still unsatisfactory. There is an urgent need for academia to fully integrate the basic research and clinical data from PC to form a research model conducive to clinical translation and promote the proper treatment of PC. This paper summarized the translation progress of mass spectrometry (MS) in the pathogenesis, diagnosis, prognosis, and PC treatment to promote the basic research results of PC into clinical diagnosis and treatment.

Keywords: diagnosis; mass spectrometry; pancreatic cancer; therapy; translational science.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Application of MS in the diagnosis and prognosis of PC.
See this image and copyright information in PMC

References

    1. Sipra Q, Islam M, Riaz IB, Zhaohui J, Babiker HM, Bekaii-Saab TS, et al. Contemporary Management of Pancreatic Cancer From an Internist Perspective. Am J Med (2020) 134(5):576–6. doi: 10.1016/j.amjmed.2020.11.009 - DOI - PubMed
    1. Turpin A, El Amrani M, Bachet JB, Pietrasz D, Schwarz L, Hammel P. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Cancers (Basel) (2020) 12(12):3866. doi: 10.3390/cancers12123866 - DOI - PMC - PubMed
    1. Bengtsson A, Andersson R, Rahm J, Ganganna K, Andersson B, Ansari D. Organoid Technology for Personalized Pancreatic Cancer Therapy. Cell Oncol (Dordr) (2021) 44(2):251–60. doi: 10.1007/s13402-021-00585-1 - DOI - PMC - PubMed
    1. McGuigan AJ, Coleman HG, McCain RS, Kelly AJ, Johnston HG, Taylor RS, et al. Immune Cell Infiltrates as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. J Pathol Clin Res (2021) 7(2):99–112. doi: 10.1002/cjp2.192 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654 - DOI - PubMed

LinkOut - more resources